HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.

Abstract
We previously established acquired resistant models for MET-tyrosine kinase inhibitors (TKIs) by continuously exposing the MET-amplified gastric cancer cell line MKN45 to MET-TKIs, PHA665752 (MKN45-PR), or GSK1363089 (MKN45-GR). We found resistant mechanisms caused by increased copy number of MET in both lines and Y1230H mutation in MKN45-PR. We also found that excessive MET signaling caused by these MET alterations resulted in intra-S-phase arrest in the absence of MET-TKIs, so that cells grew faster in the presence of MET-TKIs, a phenomenon referred to as "addiction." In this study, to investigate reversibility of the acquired resistance and "addiction" to MET-TKIs and their causative MET alterations, we sequentially cultured MKN45-PR and MKN45-GR in decreasing concentrations of MET-TKIs until they were able to grow in a drug-free condition. These "revertant" cell lines (designated MKN45-PR-RE and MKN45-GR-RE) were comparatively analyzed. Growth assay showed that both MKN45-PR-RE and MKN45-GR-RE partially lost the property of "addiction" to MET-TKIs. MKN45-GR-RE lost the property of resistance to GSK1363089, but MKN45-PR-RE retained resistance to PHA665752. Copy numbers and expression and phosphorylation of MET protein reduced in both MKN45-PR-RE and MKN45-GR-RE compared with MKN45-PR and MKN45-GR, respectively, but Y1230H mutation and biochemical resistance to PHA665752 remained in MKN45-PR-RE. The "addiction" to MET-TKIs appeared attributable to increased copy number, and the property and the MET alteration were reversible. The Y1230H mutation appeared enough in itself to keep cells resistant to MET-TKIs and was irreversible.
AuthorsYohei Funakoshi, Toru Mukohara, Roudy Chiminch Ekyalongo, Hideo Tomioka, Yu Kataoka, Yohei Shimono, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
JournalOncology research (Oncol Res) Vol. 21 Issue 6 Pg. 287-93 ( 2013) ISSN: 1555-3906 [Electronic] United States
PMID25198658 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-met
Topics
  • Carcinoma (genetics, metabolism)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • DNA Mutational Analysis
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm (genetics)
  • Gene Dosage
  • Humans
  • Mutation
  • Protein Kinase Inhibitors (pharmacology)
  • Proto-Oncogene Proteins c-met (antagonists & inhibitors, genetics)
  • Signal Transduction (drug effects)
  • Stomach Neoplasms (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: